chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Within a few days of the vaccination, I developed extreme flatulence, with frequent and copious discharges of exceedingly foul-smelling gas throughout the day, sometimes as often as four or more times within an hour. My digestion seemed sluggish and irregular, and I experienced a sense of being bloated (which the discharges somewhat relieved).   All these symptoms continued for about three weeks. At first I thought they simply had to do with something I might have eaten, but this seemed not to be the case. Throughout, my diet, dietary supplements, residence, sleep, environment, and daily routine remained the same -- and the same as they had been for months before.  Additional information for Item 18: Finally, about two weeks ago, I began taking an Ayurvedic digestive medicine (Dashamularista), once daily after lunch, which helped greatly. The discharges of gas reduced considerably in frequency and copiousness and were no longer abnormally foul-smelling. As of this day, however, flatulence still seems somewhat more than usual. Of course, I cannot unerringly testify to a cause-and-effect relationship between the vaccination and the symptoms I have described. But I see no other likely candidate for a cause.   I should mention that within the last few days I have developed mild but disturbing inflammation in the joints of both hands, particularly the knuckles. I have not had this before. I have also felt somewhat listless. (This, however, is not a symptom new for me.) in the last few days I have also developed a mild edema in both feet. But I have had this before from time to time, and the present instance might be attributable to variables such as a change in weather. (In the past this edema was diagnosed as lymphatic in origin, not circulatory.)
Flu vaccine to (R) upper arm-erythema, localized warmth at site. Seen by CFNP.
generalized red, bumpy, pruritic rash. sparce, but on every limb and on back, thorax, and abdomen. no vessicles, pustules, bullae, scaling, or excoriation.
Patient had an itchy red hive near the injection site. Patient took one dose of Benadryl and itching went away and the hive is going down.
04/14/2003: Patient complained of deep muscle pain and weakness in left arm.  Onset 2-3 days past vaccine.  Reported 1 week past vaccine.  04/18/2003: Patient states continued use, symptoms up.  "has to left affected arm in other" To consult private physician.  No redness.
Left 2  finger, tenosynovitis,  felt most back of hand, worse with extension/flexion second fingers has lasted  >24 hours, better with motrin
Patient presented from an assisted living facility to the emergency department on 9/3/2021 following a fall from a chair. He was found to be COVID-19 positive and was administered monoclonal antibodies on 9/5/2021. He remained asymptomatic during admission. He was discharged to skilled nursing facility on 9/7/2021.
Red splotches on Back and Chest since 10/04/04 AM. Fever up to 101.8 from 9/30 and 10/2
headache; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team for a Pfizer sponsored program. The reporter is the parent. Other Case identifier(s): US-PFIZER INC-202101863708 (Pfizer).  A 32-year-old male patient received bnt162b2 (BNT162B2), administration date May2021 (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose 1, Manufacturer unknown), for COVID-19 Immunization. The following information was reported: HEADACHE (non-serious) with onset 2021, outcome "unknown", described as "headache". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: My son has suffered with a headache since a week after having his second Pfizer vaccine shot in May2021. As a result, he refuses to get a booster. He has had an MRI and his brain looked normal thankfully. On a scale of 0- 10, he would rate the headache a consistent 4/5.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
This spontaneous report was received from a registered nurse referring to a patient of currently 2 years age and unspecified gender. The patient's pertinent medical history and concomitant medications were not reported. On an unknown date, the patient was vaccinated with improperly stored dose of VARIVAX with lot # L034368,expiry date 08-SEP-2017; dose, route of administration and anatomical location not reported). The doses of VARIVAX (Merck) underwent temperature excursion: 14.7F for 2 hours and 15 minutes. There were no previous temperature excursions. No symptoms were reported. No product quality complaint (PQC) was involved. No further information provided. This is one of several reports from the same reporter. Additional information has been requested.
This case was reported by a physician and described the occurrence of nodule injection site in an approximately 5-month-old female subject who was vaccinated with ROTARIX (GlaxoSmithKline), PEDIARIX, Hib and PREVNAR 13. On 27 March 2012 and 20 January 2012 the subject received 2nd dose and 1st dose of ROTARIX (unknown), unspecified dose of PEDIARIX (unknown), unspecified dose of Hib (unknown), unspecified dose of PREVNAR 13 (unknown) and on 27 March 2012, the subject experienced inappropriate age at vaccine administration with the ROTARIX vaccination. The subject was older than the indicated age for ROTARIX. ROTARIX is indicated to be administered prior to 24 weeks of age and at the second dose of ROTARIX, the subject was 7 months old. On 20 January 2012, less than one day after vaccination with Hib, PEDIARIX, PREVNAR 13, the subject experienced nodule injection site and subcutaneous nodule and less than a day after vaccination with ROTARIX the subject experienced subcutaneous nodule. The events occurred with rechallenge. On 27 March 2012, less than a day after vaccination with Hib, PEDIARIX, PREVNAR 13, the subject experienced nodule injection site and subcutaneous nodule and less than a day after vaccination with ROTARIX the subject experienced subcutaneous nodule. The subject was being evaluated by an allergist because she "is exhibiting subcutaneous nodules. This happened on 20 January 2012 and on 27 March 2012." At the time of reporting the outcome of the events was unspecified. Clarification of the original report was received from GlaxoSmithKline Medical Information and the case was corrected on 16 August 2012. ROTARIX should not have been reported as a suspect medication. This was a report for PEDIARIX. ROTARIX was considered concomitant on 20 January 2012 and was not administered on 27 March 2012 as previously reported. Thus, the inappropriate age at vaccine administration was deleted since ROTARIX was not administered on 27 March 2012. The subcutaneous nodule occurred at an injection site, but the healthcare provider did not specify that it was the PEDIARIX injection site. The subject also received the Hib vaccine and PREVNAR 13 when the PEDIARIX was administered. The event of subcutaneous nodule indicating a systemic reaction was removed, since ROTARIX was not suspect and the nodule only occurred at the injection site.
Pt states he experienced body aches and headache and diarrhea and backache a few hours after influenza vaccine was administered. Advised by provider to drink plenty of fluids and take TYLENOL or MOTRIN for body aches. Pt stated he did not plan to do this he will update provider with how he is feeling.
Information has been received from a healthcare worker referring to a patient of unknown age and gender. The patient's medical history was not reported. On 13-FEB-2015 the patient was received improperly stored VARIVAX (lot # K007979, expiration date 03-JUN-2016, dose and route unknown). Concomitant medication was not reported. No adverse effects were reported. No product quality issue (PQC) was involved. This is one of several reports received from the same source. Additional information is not expected since the reporter don't wish us to contact.
After receiving the 1st dose of the Pfizer Vaccine I developed an itching rash that lasted two weeks and spread all over my body. It started on my shoulders, neck, and upper chest area, and soon covered my entire back. It then spread to my stomach, arms, upper legs, and eventually my feet.  I used Cortizone-10, Tylenol, & Showers to relieve the itching & reported the incident to my Doctor's office. The Doctor advised to continue with Cortisone and use zyrtec or benadryl if needed. It was an extremely uncomfortable two weeks, and not knowing the extent of what was happening was concerning. Daily Log describing the daily progression of the full body rash experienced after the Pfizer Covid19 Vaccine: Wed 9/8/21 11:40am Received Pfizer Covid Vaccine Thu 9/9 noticed slight itch on shoulders by end of day Fri 9/10 noticeable rash on shoulders by end of day Fri. Started treating daily with Cortisone-10, Tylenol, Showers, to relieve itching & discomfort Sat 9/11 itchy rash on entire back, chest & neck  Sun 9/12 itchy rash on entire back, chest & neck worsening Mon 9/13 itchy rash on entire back, chest & neck worsening  Reported the symptoms to the Dr's Office Tue 9/14 itchy rash on entire back, chest & neck Wed 9/15 itchy rash on entire back, chest & neck spreading to arms, stomach, upper legs Thu 9/16 slight fade on shoulders & upper back, itching upper legs & arms Fri 9/17 still spreading on upper legs & arms Sat 9/18 Arms and back itching, still spreading to thighs, upper legs, feet. Slight fade on back & upper chest.  Sun 9/19 fading on back, chest & upper arms, but still itching. Forearms & upper legs, thighs, itching. Mon 9/20 Back, chest, stomach, upper arms fading. Forearms, upper legs fading but still itch. Rash spread to feet, but not noticeable on shins or ankles.. Tue 9/21 Rash fading, slight itch on forearms,  No Cortisone-10 today Wed 9/22 Rash present but fading on thighs Thu 9/23 Mostly faded. Fri 9/24 Mostly faded.
5 min after injections given, mom approached RN asking about the child having a reaction to one of the shots. On RAT, less than 1/2 inch from ProQuad injection site there was a hiv approx 1.5 x 2cm with an area of warmth and redness approx 3.5 x 4 cm. Benadryl 12.5mg given p.o and approx 15-20 min after med dosing hive gone but redness remained.
This spontaneous report as received from a registered nurse refers to an unspecified number of patients of unknown age and gender. Information regarding relevant medical history and concurrent condition were not reported. Since 07-OCT-2015 (until the reporting time of 03-DEC-2015), the patients were vaccinated with improperly stored ZOSTAVAX (lot # L028281, expiration date 28-OCT-2016, dose and route not reported). Information regarding concomitant medications was not reported. No adverse effect reported. This is one of several reports received from the same source. Additional information has been requested.
I developed a rash on my left upper arm, around the injection site, that subsequently formed across part of my back and all of the front of my neck. It still remains today, 3/17/2013. I also had some muscle aches associated with the injection, but nothing to really complain about.
First 3 weeks I experienced a mild constant cough. Then (after 4 weeks) I experienced vertigo and developed a an ear infection with pulsatile tinnitus since. 3 weeks later I still have it.
Arm Pain Chest Pain Nausea Chills/fever Became unable to walk because of muscle weakness, fell and couldn't get up. Difficulty urinating  Transport to emergency room, tests for infection, assigned Tylenol for fever, fluids and rest.
Mother reported raised red, indurated, warm area on (R) arm, approx 2 inches x 0.5 inches. Painful. No fever. Advised ice, ibuprofen, follow-up PRN or to ER for hives/perioral swelling.
Developed COVID-19 after Moderna Dose 3; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (Developed COVID-19 after Moderna Dose 3) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was reported.  The patient's past medical history included Drug allergy. Concomitant products included ATORVASTATIN CALCIUM (LIPITOR) from an unknown date to 12-May-2022 for an unknown indication.   On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (Developed COVID-19 after Moderna Dose 3). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 13-May-2021 to 17-May-2021 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (Developed COVID-19 after Moderna Dose 3) outcome was unknown.            The patient was taking other medications/products within 2 weeks of starting COVID-19 treatment. Concomitant product reported also included Lexipro [sic].  Device Date was reported as '23May2022'.  Company Comment: This spontaneous case concerns a 55-year-old, female patient with past drug history of administration of two doses of the mRNA-1273 vaccine, who experienced the unexpected, non-serious AESI of COVID-19. The event occurred approximately 6 months after receiving the third dose of the mRNA-1273 vaccine. The patient developed COVID-19, however, no symptoms were reported. She took and completed a 5-day course of Paxlovid (nirmatrelvir, ritonavir) from 13May2022 to 17May2022. It was reported that the patient developed rebound COVID-19 unknown number of days after treatment with Paxlovid. No additional details were provided at the time of the report. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report.   This case was linked to MOD-2022-576751 (Patient Link).; Sender's Comments: This spontaneous case concerns a 55-year-old, female patient with past drug history of administration of two doses of the mRNA-1273 vaccine, who experienced the unexpected, non-serious AESI of COVID-19. The event occurred approximately 6 months after receiving the third dose of the mRNA-1273 vaccine. The patient developed COVID-19, however, no symptoms were reported. She took and completed a 5-day course of Paxlovid (nirmatrelvir, ritonavir) from 13May2022 to 17May2022. It was reported that the patient developed rebound COVID-19 unknown number of days after treatment with Paxlovid. No additional details were provided at the time of the report. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report.
She sat down after getting shot then started to lean forward after saying she was nauseous. Rph caught her as she started to lean forward and she almost fell but I was able to get her to turn sideways and instead lay down on bench rather than fall forward.  So she basically fainted for a minute and then laid for awhile while 911 was called. Ambulance arrived and patient remained conscious.
4 hours after shot eyes red and face red, throat felt tight. School nurse gave diphenhydramine unknown dose and called ambulance.
contracted COVID-19. Symptoms may have begun on July 1 or 2, 2022. On July 4. I knew I was sick and did a home test that was negative. On July 5, I went to local pharmacy for a PCR test and was notified that I tested positive.  I quarantined until Sunday, July 10 at which point, I was vigilant about masking and distancing for another 4-5 days. symptoms were fever up to 101, persisted at about 100.5 for three days, cough, sore throat, headache, body ache, fatigue, loss of taste, loss of appetite, possible diarrhea. (I have colitis so it's hard to know if it was the COVID or that)
pain went from her neck to eye; dizziness, needs to use the wall to walk down the hall; severe headaches; pain went from her neck to eye; A spontaneous report was received from a consumer concerning a 69 years old female  patient who received Moderna's Covid 19 vaccine and experienced severe headaches, pain from her neck to eye and dizziness.   The patient's medical history was not provided.No relevant concomitant medications were provided.   The patient received their first of two planned doses of mRNA-1273 (Batch number: 037K20A), intramuscularly,in her left arm on 9-Jan-2021. On 12-Jan-2021, the patient experienced severe headache. The patient also stated that pain went from her neck to eye.She also experienced dizziness and she needs to use the wall for aid as she walks down the hall.( Dizziness ensued once she lays down)  Lab data was not provided.   Treatment information included Ibuprofen.    Action taken with mRNA-1273 in response to the events was not provided.  The outcome of the event was unknown.
suspected vaccination failure; shingles; still have scars; It was painful; This case was reported by a consumer via  interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingles vaccine and the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles, scar and pain. On an unknown date, the outcome of the vaccination failure was unknown and the outcome of the shingles and pain were recovered/resolved and the outcome of the scar was not recovered/not resolved.   It was unknown if the reporter considered the vaccination failure, shingles, scar and pain to be related to Shingles vaccine and Shingles vaccine.  Additional details were provided as follows: The patient self-reported this case. The age at vaccination was not reported. The patient stated he/she never had chicken pox and had two shingles shot and got shingles, further stated, it was painful and took several weeks to go away. The patient took pills and cream, still had scars. The patient hoped he/she did not get it again. The patient asked if the shot helped. This case was considered as suspected vaccination failure as details regarding time to onset and laboratory test confirming shingles were unknown at the time of reporting. The follow-up would not be possible as no contact details were available.
Warm to touch; Itchiness; Swollen lymph nodes; Small lump, plum sized lump; Pain at injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE MASS (Small lump, plum sized lump), FEELING HOT (Warm to touch), PRURITUS (Itchiness), VACCINATION SITE PAIN (Pain at injection site) and LYMPHADENOPATHY (Swollen lymph nodes) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 001A21A and 015M20A) for COVID-19 vaccination.     The patient's past medical history included Lymphedema (cancer survivor. Had episodes of lymphedema before vaccination). Concurrent medical conditions included Allergy.   On 06-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 09-Mar-2021, the patient experienced VACCINATION SITE MASS (Small lump, plum sized lump) and VACCINATION SITE PAIN (Pain at injection site). On 11-Mar-2021, the patient experienced FEELING HOT (Warm to touch), PRURITUS (Itchiness) and LYMPHADENOPATHY (Swollen lymph nodes). At the time of the report, VACCINATION SITE MASS (Small lump, plum sized lump), FEELING HOT (Warm to touch), PRURITUS (Itchiness), VACCINATION SITE PAIN (Pain at injection site) and LYMPHADENOPATHY (Swollen lymph nodes) outcome was unknown.            No concomitant medications were provided by the reporter.   Patient had a small lump on 09-Mar-2021 which became a plum sized lump on 11-Mar-2021. Treatment information was not provided.  Action taken with mRNA-1273 in response to the events was not applicable.
Blister Type Rash on Left lower leg , stomach and between my legs and also blisters on the bottom of my feet.  The rash started roughly 10 days after my first dose of the Pfizer Vaccine.  The lower left leg stays swollen with red raised bumps and constantly itches.  I now have a knot or lump in the lower leg that is very tender to the touch.  The rash on my stomach and between my legs is read with raised bumps and constantly itches, it have severely affected my sleep.  I have had 2 virtual appoints with the dermatologist and 1 in office visit.  I have been prescribe steroids and 3 different types of ointment and nothing has cleared the rash.
Case number PHHY2013US117745 is an initial report received from Vaccine Adverse Event Reporting System (VAERS reference number: 491207). This report refers to a female neonate patient. Current condition of this patient include gelatin allergy and allergic to varicella, DTaP and flu vaccines. She was vaccinated with her first seasonal influenza vaccine (manufacturer and batch number: not reported) on an unspecified date and she experienced hives and on an unknown date. Outcome of the event, seriousness and causality were not reported.